Protective Effect of D-β-Hydroxybutyrate on Corneal Epithelia in Dry Eye Conditions through Suppression of Apoptosis

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 11, 2003, Pages 4682-4688

  Nakamura, Shigeru ^a,c   Shibuya, Michiko ^a   Saito, Yasukazu ^a   Nakashima, Hideo ^a   Saito, Fumio ^a   Higuchi, Akihiro ^b   Tsubota, Kazuo ^b  

^a Ophtecs Corporation   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c Ophtecs Corporation   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; BUFFER; FLUORESCENT DYE; PHOSPHATE; SODIUM CHLORIDE;

AIRFLOW; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA EROSION; DESICCATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRY EYE; EVAPORATION; HISTOPATHOLOGY; HUMIDITY; LACRIMAL FLUID; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM;

3-HYDROXYBUTYRIC ACID; ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; BLOOD; CELL SURVIVAL; CORNEAL DISEASES; DRY EYE SYNDROMES; EPITHELIUM, CORNEAL; MALE; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0142139239     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0198     Document Type: Article

References (39)

1. Tsubota K, Higuchi A. Serum application for the treatment of ocular surface disorders. Int Ophthalmol Clin. 2000;40:113-122.
2. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459-461.
3. Tsubota K, Satake Y, Shimazaki J. Treatment of severe dry eye. Lancet. 1996;348:123.
4. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25:1101-1103.
5. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106:1984-1989.
6. Ferreira de Souza R, Kruse FE, Seitz B. Autologous serum for otherwise therapy resistant corneal epithelial defects: prospective report on the first 70 eyes. Klin Monatsbl Augenheilkd. 2001;218:720-726.
7. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20:802-806.
8. Geerling G, Hartwig D. Autologous serum-eye-drops for ocular surface disorders. a literature review and recommendations for their application. Ophthalmologe. 2002;99:949-959.
9. Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev. 1980;60:143-187.
10. Mackey EM. The significance of ketones. J Clin Endocrinol. 1943;3:101-110.
11. Katayama M, Hiraide A, Sugimoto H, Yoshioka T, Sugimoto T. Effect of ketone bodies on hyperglycemia and lactic acidemia in hemorrhagic stress. JPEN J Parenter Enteral Nutr. 1994;18:442-446.
12. Hiraide A, Katayama M, Mizobata Y, Sugimoto H, Yoshioka T, Sugimoto T. Effect of sodium D-3-hydroxybutyrate on amino acidemia in hemorrhagic hypotension. Eur Surg Res. 1991;23:250-255.
13. Mizobata Y, Hiraide A, Katayama M, Sugimoto H, Yoshioka T, Sugimoto T. Oxidation of D(-)3-hydroxybutyrate administered to rats with extensive burns. Surg Today. 1996;26:173-178.
14. Suzuki M, Suzuki M, Sato K, et al. Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats. Jpn J Pharmacol. 2001;87:143-150.
15. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci USA. 2000;97:5440-5444.
16. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life. 2001;51:241-247.
17. Raunio RP, Leivo PV, Kuusinen AM. Bioluminescent assay of D-3-hydroxybutyrate in serum. J Biolumin Chemilumin. 1986;1:11-14.
18. Debbasch C, Pisella PJ, De Saint Jean M, Rat P, Warnet JM, Baudouin C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2001;42:2525-2533.
19. Sakamoto R, Bennett ES, Henry VA, et al. The phenol red thread tear test: a cross-cultural study. Invest Ophthalmol Vis Sci. 1993;34:3510-3514.
20. Gao J, Gelber Schwalb TA, Addeo JV, Stern ME. Apoptosis in the lacrimal gland and conjunctiva of dry eye dogs. Adv Exp Med Biol. 1998;438:453-460.
21. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44:124-129.
22. Wyllie AH, Beattie GJ, Hargreaves AD. Chromatin changes in apoptosis. Histocbem J. 1981;13:681-692.
23. Kroemer G, Dallaporta B, Resche Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619-642.
24. Maitchouk DY, Beuerman RW, Ohta T, Stern M, Varnell RJ. Tear production after unilateral removal of the main lacrimal gland in squirrel monkeys. Arch Ophthalmol. 2000;118;246-252.
25. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca: a useful model for human keratoconjunctivitis sicca-treatment with cyclosporine eye drops. Arcb Ophthalmol. 1989;107:1210-1216.
26. Moore CP, McHugh JB, Thorne JG, Phillips TE. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Invest Ophthalmol Vis Sci. 2001;42:653-659.
27. Gilger BC, Rose PD, Davidson MG, Roberts SM, Miller T. Low-dose oral administration of interferon-alpha for the treatment of immune-mediated keratoconjunctivitis sicca in dogs. J Interferon Cytokine. 1999;19:901-905.
28. Hicks SJ, Corfield AP, Kaswan RL, et al. Biochemical analysis of ocular surface mucin abnormalities in dry eye: the canine model. Exp Eye Res. 1998;67:709-718.
29. Fujihara T, Nagano T, Nakamura M, Shirasawa E. Establishment of a rabbit short-term dr), eye model. J Ocul Pharmacol Ther. 1995;11:503-508.
30. Burgalassi S, Panichi L, Chetoni P, Saettone MF, Boldrini E. Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes. Ophthalmic Res. 1999;31:229-235.
31. Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96-100.
32. Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002;43:632-638.
33. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res. 1998;17:565-596.
34. Wilson SE. Role of apoptosis in wound healing in the cornea. Cornea. 2000;19:S7-S12.
35. Li Q, Ashraf MF, Bekoe NA, Stark WJ, Chan CC, O'Brien TP. The role of apoptosis in the early corneal wound healing after excimer laser keratectomy in the rat. Graefes Arch Clin Exp Ophthalmol. 2000;238:853-860.
36. Lu L, Reinach PS, Kao WW. Corneal epithelial wound healing. Exp Biol Med. 2001;226:653-664.
37. Wilson SE, Mohan RR, Hong JW, Lee JS, Choi R, Mohan RR. The wound healing response after laser in situ keratomileusis and photorefractive keratectomy: elusive control of biological variability and effect on custom laser vision correction. Arch Ophthalmol. 2001;119:889-896.
38. Pflugfelder SC. Tear fluid influence on the ocular surface. Adv Exp Med Biol. 1998;438:611-617.
39. Kashiwaya Y, King MT, Veech RL. Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am J Cardiol. 1997;80:50A-64A.